Company news
ALX Oncology Holdings Inc. news in 2026
ALX Oncology Holdings Inc.'s news releases, calls and decks from 2026, newest first.
ALX Oncology Reports Third Quarter 2026 Financial Results and Provides Corporate Update
November 16, 2026
ALX Oncology to Present at Upcoming Investor Conferences
November 10, 2026
ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
September 28, 2026
ALX Oncology to Present at Upcoming Investor Conferences in September
September 2, 2026
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 6, 2026
ALX Oncology Appoints Scott Garland as Chairman of the Board and Michael Listgarten as General Counsel
June 30, 2026
ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York
June 1, 2026
ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 8, 2026
ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026
April 30, 2026
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
April 17, 2026
ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer
April 12, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
March 2, 2026
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
February 26, 2026
ALX Oncology to Present at Upcoming Investor Conferences in Q1 2026
February 19, 2026
ALX Oncology to Report Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026
February 19, 2026
ALX Oncology Announces Pricing of Underwritten Offering
January 30, 2026
New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer
January 30, 2026
ALX Oncology to Present at the 44th Annual J.P. Morgan Healthcare Conference
January 8, 2026
ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004
January 8, 2026
Calls in 2026
Decks in 2026
- Investor Presentation (August 2026)
Investor deck · 36 slides · August 2026
- Q1 2026 Earnings Presentation
Earnings · 38 slides · May 8, 2026
- Q4 2025 Earnings Presentation
Earnings · 37 slides · Feb 27, 2026